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This study evaluates the overall survival and disease free survival of melanoma patients that were treated with an autologous
melanoma cell vaccine, administered as a post-operative adjuvant. Included are 43 patients with totally resected metastatic
melanoma (28-AJCC stage III, 15-AJCC stage IV), with a median follow up of 34 months (6–62). The treatment consisted of
eight doses of a vaccine made of 10–25610
6 autologous melanoma cells either released from the surgical specimen or
grown in cell cultures. Tumour cells were conjugated with hapten dinitrophenyl, mixed with Bacille Calmette Gue ￿rin and
irradiated to 110 Gy. Both disease free survival and overall survival were found to be correlated with intensity of evolving
delayed type hypersensitivity to subcutaneous injection of unmodiﬁed melanoma cells. Patients with a delayed type
hypersensitivity reaction of 510 mm had a median disease free survival of 17 months (mean 35 months) and a mean overall
survival of 63 months (median not reached). In contrast, patients with a negative or weak delayed type hypersensitivity had a
median disease free survival of 9 months (relative risk of recurrence=4.5, P=0.001), and a median overall survival of 16
months (relative risk of death=15, P=0.001). Stage III patients with a positive delayed type hypersensitivity reaction had an
improved disease free survival of 16 months and a mean overall survival of 38 months, whereas patients with a negative
delayed type hypersensitivity had a median disease free survival of 7 months (relative risk=4.5, P=0.02) and a median overall
survival of 16 months (relative risk=9.5, P=0.005). The adjuvant administration of autologous melanoma vaccine was
associated with improved disease-free and overall survival to selected patients who successfully attained anti-melanoma
reactivity as detected by positive delayed type hypersensitivity reactions to unmodiﬁed melanoma cells.
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Patients suffering from malignant melanoma with metastases to
regional lymph nodes, satellites and metastases in-transit are
deﬁned as stage III (The new American Joint Committee on Cancer
(AJCC) classiﬁcation) (Balch et al, 2000). More than half of these
patients die of their disease within 2 years (Cascinelli et al,
1984), and the prospects are even worse for patients with distant
metastases (AJCC stage IV). Even when surgical excision is feasible,
the 2 year survival rates for these patients range only from 14 to
26% (Eton et al, 1998). Presently, the issue of adjuvant treatment
for these high-risk patients is unsettled. Based on ECOG and inter-
group studies E1684 (Kirkwood et al, 1996), E1690 (Kirkwood et
al, 2000) and E1694 (Kirkwood et al, 2001), the authors stress that
accumulated data reveal reduction in the hazard ratio for relapse
and death for patients (AJCC stage IIB and III) treated with maxi-
mally tolerated dose of interferon-alfa 2b. Opponents, however,
doubt whether the considerable toxicity of this protocol justiﬁes
the therapeutic advantage (Spitler, 2001). Furthermore, premature
analysis of EORTC No. 18952 study hints towards emerging survi-
val beneﬁt for patients treated with an intermediate-low dose of
IFN-alfa 2b whereas the intermediate-high dose schedule is not
superior to control (Eggermont, 2001). Overall, the adjuvant poten-
tial of immunotherapeutic strategies is supported by these studies.
Melanoma vaccines are an attractive alternative approach for an
adjuvant treatment. It is true that their value in metastatic disease
is limited: the response rates range only from 5 to 15%, and these
positive responses are mainly limited to subcutaneous metastases
(Mitchell et al, 1990; Morton et al, 1992; Sato, 1996; Eton et al,
1998). In spite of this, a much larger percentage of patients treated
with melanoma vaccines develop deﬁnite immune reactions.
Although in most cases these reactions fail to translate into clinical
tumour regressions, improved survival has been repeatedly
reported for those patients who develop anti-melanoma immune
responses (Bystryn et al, 1992; Livingston et al, 1994; Hsueh et
al, 1998; Baars et al, 2000). These observations have led to several
ongoing studies for the evaluation of the adjuvant role of active
immunotherapy for high-risk melanoma patients. The assumption
is that the early induction of anti-melanoma immunity might
prolong disease free and/or overall survival of AJCC stage III and
IV patients suffering from malignant melanoma.
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Berd and colleagues. Their vaccine is composed of autologous
melanoma cells conjugated with a hapten-dinitrophenyl (DNP),
irradiated and mixed with Bacille Calmete Gue ￿rin (BCG). They
administered this vaccine as an adjuvant treatment to patients with
AJCC stage III and stage IV resectable nodal disease. In comparison
to control patients, this method has yielded improved disease free
and overall survival (Berd et al, 1997).
Encouraged by earlier work of this group, we chose to use this
method of Berd and colleagues and to further extend it by using
melanoma cell cultures from the primary tumour. This modiﬁca-
tion of the method allowed us to include patients with small
tumour volumes into the program. Here we report our results with
the ﬁrst 43 stage III and IV cutaneous and non-cutaneous melano-
ma patients whom we treated using this approach as a
postoperative adjuvant therapy for resectable disease. We did not
include a no-treatment arm in our study and therefore will be
unable to calculate the risk reduction ratio of the group. Neverthe-
less, a strong prognostic marker became apparent during the follow
up period: patients who developed positive skin reaction to subcu-
taneous injection of their own melanoma cells faired signiﬁcantly
better than those who failed to do so. We suggest that their
improved survival attests to the adjuvant effect of autologous mela-
noma vaccine.
PATIENTS AND METHODS
Patients
The patients included in this study were grouped in two categories:
(1) Twenty-eight patients with the modiﬁed AJCC stage III cuta-
neous malignant melanoma metastatic to the regional lymph
node (macrometastases, N1-3/b), ﬁve of them also having satellites
and metastases in transit (stage IIIC); (2) 15 patients with cuta-
neous malignant melanoma metastatic to viscera (AJCC stage IV)
or with metastatic non-cutaneous melanoma (2-rectal melanoma,
4-ocular melanoma, 1-laryngeal melanoma). For clinical details
see Table 1.
To be eligible for our study, patients had to have undergone
complete surgical excision of metastatic disease and be found
disease free based on whole body CT scan performed less than 3
weeks prior to surgery. In addition, patients had to have a positive
skin reaction to at least one out of four recall antigens: PPD, candi-
din, trychophytin, and tetanus toxoid. A positive reaction was
deﬁned as an erythema larger than 5 mm in diameter. The study
was approved by the Institutional Review Board and informed
consent was obtained before any therapy was administered.
Four of the patients received radiotherapy after surgery and
prior to the initiation of the vaccinations. One of these received
whole brain irradiation for a single brain metastasis, and the other
three received radiation treatment to the abdominal wall or to
cervical lymph nodes for close margins and for extracapsular lymph
node invasion. We started the vaccine procedure for these four
patients 1 month after their radiotherapy was completed. Although
these patients received radiotherapy prior to their inclusion in our
study, they remained immune competent, which we ascertained by
their skin tests. After the resection of their liver metastases, two
patients with ocular melanoma had received four courses of an
intra-arterial hepatic infusion of fotemustine before we started
the vaccine procedure. Four patients were referred to us with meta-
static disease after they failed to respond to either low dose (one
patient) or high dose (three patients) interferon-a adjuvant ther-
apy.
Vaccine preparation
Tumour specimens were procured fresh and sterile. For large
tumour bulks, cells were extracted by mechanically or by enzymatic
dissociation with collagenase and DNAse (Sigma, St. Louis, MO,
USA), frozen in a controlled rate freezer, and stored in liquid
nitrogen in a medium containing 2.5% human albumin and 20%
DMSO until needed. If the total cell yield was less than
200610
6 cells, cell suspensions were put into culture bottles with
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Gibco BRL,
Gaithersburg, MD, USA), 10% foetal calf serum (Gibco BRL),
HEPES (1:500), pen-strep (1:100) and glutamin (1:100) and
expanded to the required number, necessary for preparation of at
least eight vaccine doses, of 10–25610
6 cells each. Culturing the
cells resulted in the preferential selection of melanoma cells, so that
the vaccine ﬁnally consisted of puriﬁed melanoma cells.
When we were unable to dissociate the cells mechanically – as
in the case of a small specimen or a dense connective tissue –
tumours were cut into pieces of less than 1 mm
3 in size, put on
a6 0m m
2 plastic dish (Nunc), and then glued to the dish with
drops of foetal calf serum (Gibco BRL). Culture medium was
added to the dish 24 h later. When cell growth was observed at
the periphery of tumour pieces, we transferred the cell mass to a
culture bottle. To assure melanocytic progeny, staining of slides
covered by cultured cells was performed with monoclonal antibo-
dies S-100 and HMB-45, using the alkaline phosphatase anti-
alkaline phosphatase (APAAP) reaction (Zymed Inc., San Francis-
co, CA, USA). Positive staining of more than 50% of cells with
at least one of these antibodies was required.
On treatment day, the cells were thawed, washed and irradiated
to 110 Gy. A sample was stained with Trypan blue and counted
after irradiation. Conjugation of melanoma cells with DNP was
performed by the method of Miller and Claman (1976). Brieﬂy,
melanoma cells were washed with Hanks balanced solution-no
HSA, resuspended to a concentration of 5610
6 ml
71, mixed,
incubated for 30 min and washed again. Prior to vaccination an
appropriate amount of BCG was added, starting with a dilution
of 1:50 and reaching 1:500–1000, according to the resulting
granuloma at vaccination site.
Vaccination procedure (see Table 2)
On day 1, patients received 300 mg m
2 of intravenous cyclopho-
sphamide. On days 4 and 5, patients were sensitised to DNP by
applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma)
topically to the inner aspect of the arm. On day 18, patients
received a second dose of 300 mg m
2 cyclophosphamide. On day
21, the prepared vaccine was injected into three adjacent sites on
the upper arm or thigh, avoiding limbs where lymph node dissec-
tion had been previously performed. Seven additional doses of the
vaccine were administered at intervals of 21–28 days. Before
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Table 1 Clinical stage and site of metastases
No.
AJCC stage III 28 (65%)
LN 23
LN+satellites/in transit 5
AJCC stage IV 15 (35%)
Lung 1
Liver 5*
Adrenal 1
Peritoneum 1**
Lung+ST 1
Lung+intestine 1
Lung+LN 1
Bone+brain 1
Laryngeal melanoma+4 lymph node basins 1
Rectal melanoma+mesenteric LN 2
LN=lymph node; ST=soft tissue. *Four with a primary ocular melanoma. **Primary
ocular melanoma.
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3
of cyclophosphamide was administered i.v. Patients were evaluated
periodically every 2 months. These evaluations included a physical
examination, a complete blood count, and liver function tests. A
chest X-ray was performed every 3 months and a total body CT
scan was made every 6 months.
DTH evaluation
Skin testing to evaluate delayed type hypersensitivity to autologous
melanoma cells was performed by intradermal injection of 1–
3610
6 unmodiﬁed melanoma cells irradiated to a dose of
170 Gy. To avoid contamination with foreign proteins and chemi-
cals, the cells were triple washed before injection. DTH was
measured by the maximal diameter of erythema at 48 h after the
injection of the vaccine. Erythema smaller than 5 mm was deﬁned
as a negative reaction. We arbitrarily chose the value of 10 mm of
erythema to discriminate between weak DTH (510 mm) and
strong DTH (510 mm). Patients were also skin tested to 3610
6
unmodiﬁed autologous lymphocytes.
Statistical analysis
The analysis focused on the impact of DTH on OS and DFS. The OS
and DFS were estimated by the Kaplan-Meier’s method. Signiﬁcance
was calculated by the log rank test. To further validate the effect of
DTH on survival, a Cox proportional hazards method was used to
adjust for the following covariates: age (460, 460 years), gender,
time elapsing from surgery to the ﬁrst vaccination (43, 43 months),
and stage (III, IV). A relative risk (RR) of more than 1 denotes the
increased risk of death or recurrence for patients with a negative or
a weak DTH response as compared to patients with a strong positive
DTH, calculated by the Cox model. The model was built for all
patients (adjusted for stage) and for stage III patients only, because
of the importance of this group.
RESULTS
All of the patients that we entered into the study have been
included in our analysis. Thirty-three (73%) of these patients
completed full schedules; 11 (27%) of the patients suffered disease
recurrence while on treatment. Median follow up period is 34
months (range: 6–62)
General results
Using the Kaplan-Meier method and the log rank test, the single
parameter that was strongly correlated in a univariate analysis with
overall survival (OS) and disease-free survival (DFS) was the DTH
response. The Cox proportional hazards model, adjusted for age,
gender, time from surgery and stage conﬁrmed this ﬁnding (Table
3). DFS and OS were analysed for DTH 510 mm (negative or
weak DTH) vs DTH 510 mm (strong positive DTH). Twenty-
six patients (60%) attained strong positive DTH whereas 17
patients (40%) had only weak or negative DTH. Patients who
failed to attain a strong DTH had an increased risk of 15 (95%
conﬁdence interval (CI) 3–76; P=0.001) to die of their disease
and a relative risk of 4.5 (95% CI 1.8–11; P=0.001) to have a
disease recurrence. Current patient status with respect to DTH
response is shown in Figure 1. For the whole group, the mean
DFS was 24 months (median 12 months) and the mean OS was
48 months (restricted for 62 months). Fortunately, at this time
the median OS has not been reached. Patients that attained a
DTH reaction 510 mm a median DFS of 17 months, and a mean
OS of 63 months (median not reached yet). Patients that failed to
attain DTH or had only a weak reaction had a median DFS of 9
months and a median OS of 16 months (Table 3, Figure 2).
Interactions between DTH and the covariates of age, gender,
time from surgery and stage for OS and DFS were tested and found
not signiﬁcant using the Cox model with an interaction term.
Stage III patients
The vaccine was administered to 28 AJCC stage III patients whose
median DFS was 12 months and median OS was 31 months.
Patients that attained a DTH reaction 410 mm had a median
DFS of 16 months and a mean OS of 38 months (restricted for
48 months, median not reached). Patients with a negative or weak
(510 mm) DTH had a median DFS of 7 months and a median OS
of 16 months (Table 4). Using the Cox model, the estimated RR of
death for patients who failed to attain positive DTH was 9.6 (95%
CI 2–47; P=0.005) and the RR for recurrence was 4.5 (95% CI
1.2–16; P=0.02).
Stage IV patients
The vaccine was administered to 15 AJCC stage IV cutaneous and
non-cutaneous, metastatic melanoma patients, whose median DFS
was 12 months and median OS was not reached yet (mean 56
months). This group is too small and heterogenous to be sub
analysed. However, even for this small group, differences in OS
and DFS according to patients’ DTH status almost reach statistical
signiﬁcance. All eight patients with positive DTH are alive.
One patient with ocular melanoma metastatic to the liver, who had
intra-hepatic artery infusions of fotemustine, had extremely strong
DTH reactions (erythema and oedema of 430 mm in diameter); this
patient has been disease-free for 47 months. Another patient, with
rectal melanoma and metastatic mesenteric lymph nodes, had a
DTH reaction of 45 mm. She has been disease free for 54 months;
her last DTH testing, done 36 months after the completion of full
vaccination schedule, still revealed a 35 mm erythema.
Toxicity
No signiﬁcant systemic toxicity was observed in any of the patients.
Vaccination sites resolved leaving depressed atrophic scars.
DISCUSSION
Stage III and IV melanoma patients face a grave prognosis. The
overall 2-year survival for patients with lymph node metastases
(stage III) is 29–38% and their median DFS is 12 months. Patients
with distant metastases do even more poorly. Eton (1998a)
reported that the 2-year survival for patients with one organ invol-
vement is 14%, for multiple subcutaneous metastases – 17%, and
for lung metastases alone – 26%. The median survival period for
these stage IV patients was reported to be 7.5, 15 and 8 months,
respectively (Barth et al, 1995). Most patients who can be rendered
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Table 2 Treatment schedule
Day Treatment
1 Cyclophosphamide
4 Sensitisation to DNP
5 Sensitisation to DNP
18 Cyclophosphamide
21 Vaccine dose 1
46 Cyclophosphamide
49 Vaccine dose 2
77 Vaccine dose 3
105 Vaccine dose 4
133 Vaccine dose 5
161 Vaccine dose 6
189 Vaccine dose 7
217 Vaccine dose 8
Adjuvant autologous melanoma vaccine
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British Journal of Cancer (2002) 86(10), 1534–1539 ã 2002 Cancer Research UKapparently ‘disease free’ by surgical excision of all detectable
disease, harbour micrometastases and eventually develop evident
metastases and succumb to their disease.
Attempts towards improving the dismal prognosis of these
patients by adjuvant conventional therapies, that is chemotherapy
with DTIC, have not proven to be beneﬁcial. This discouraging
situation has stimulated researchers to seek different approaches,
of which the use of immunotherapy is one of the most compelling.
There are many examples supporting the suggestion that the
immune system has an important role in the development of
anti-melanoma reactivity. These examples include cases of sponta-
neous regression of primary and metastatic melanoma, and also the
development of vitiligo in melanoma patients. These phenomena
have been accompanied by various circulating anti-melanocyte
antibodies and melanoma speciﬁc cytotoxicity conveyed by tumour
inﬁltrating lymphocytes (Naughton et al, 1983; Bottger et al, 1992;
Kawakami et al, 1994). Immunotherapy is most likely to eradicate
metastatic disease when the tumour burden is minimal and when
the host has not yet become immunosuppressed either by tumour
itself (Akiyama et al, 1983), or by various chemotherapeutic agents.
Various vaccination strategies against melanoma are based on
presenting melanoma-associated antigens (MAAs) or peptides to
elicit speciﬁc cytotoxicity against tumour cells (Hersey et al,
1986; Bystryn et al, 1992; Livingston et al, 1994; Mitchell et al,
1997; Eton et al, 1998b; Hsueh et al, 1998; Rosenberg et al,
1998). The source of these antigens can either be whole or frag-
mented melanoma cells or, alternately, puriﬁed peptides, speciﬁc
of melanoma.
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Table 3 Mean and median disease free survival (DFS) and overall survival
(OS) of all patients according to DTH response. DFS and OS estimated by
Kaplan-Meier method, relative risk (RR) estimated by the Cox proportional
hazards regression model
DTH
DFS (months)
(95% CI)
OS (months)
(95% CI)
(No. RR RR
patients) Mean Median (95% CI*) Mean Median (95% CI*)
Negative or weak 11 9 4.5 26 16 15
DTH (17) (6–17) (6–12) (2–11) (17–35) (10–21) (3–76)
Positive DTH 35 17 1 63 Not 1
(26) (22–48) (3–30) (54–72) reached
P value 0.001 0.001 0.0004 0.001
*CI=Conﬁdence Interval.
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Figure 1 Current patient status with respect to DTH response. The
number of patients in each of three categories. NED: no evidence of dis-
ease; AWD: alive with disease; Exitus: deceased. In each of these cate-
gories, the patients were divided into two groups according to the
pattern of the delayed type hyper-sensitivity (DTH).
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Figure 2 Kaplan-Meier estimates of (A) overall survival and (B) disease
free survival as a function of DTH status for all patients.
Table 4 Disease free survival (DFS) and overall survival (OS) of stage III
patients according to DTH response. DFS and OS estimated by the Kaplan-
Meier method, relative risk (RR) estimated by the Cox proportional
hazards regression model
DTH
DFS (months)
(95% CI)
OS (months)
(95% CI)
(No. patients) Mean Median RR Mean Median RR
Negative or weak 9 7 4.5 19 16 9.6
DTH (11) (6–12) (4–10) (1.2–16) (12–25) (14–17) (2–47)
Positve DTH 20 16 1 38 Not 1
(15) (13–26) (10–22) (31–45) reached
P value 0.015 0.02 0.009 0.005
*CI=Conﬁdence Interval.
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vaccines is that the diverse antigens in the vaccine would be
presented in the context of the patient’s own Major Histocompati-
bilty Complex (MHC). This condition is mandatory for the
recognition of cytotoxic T lymphocytes (CTLs) (Imro et al,
1999). To date, the largest published study on the use of autolo-
gous melanoma vaccine as a post-operative adjuvant for stage III
cancer patients is the study by Berd and colleagues that they under-
took in 1997 (Berd et al, 1997). They reported survival rates for
vaccinated patients that were signiﬁcantly higher than those of
control patients treated by surgery alone. Vaccinated patients that
became DTH positive had signiﬁcantly improved survival rates
(71% 5-year survival) compared to patients that remained DTH
negative (49% 5-year survival). Overall, the projected 5-year DFS
rates for all their (DTH positive and DTH negative) vaccinated
patients was 45% and the projected 5-year OS rate was 58%.
The toxicity associated with these treatments was negligible. Latest
results of an expanded population of 214 patients and extended
follow-up show a 5 year survival rate of 47%. Similar to our group,
Berd et al (2001) has repeated the observation that the induction of
DTH to unmodiﬁed tumour cells was associated with signiﬁcantly
longer 5-year survival (DTH 55 mm=69%, DTH 55 mm=33%,
P50.001). A disadvantage of using autologous melanoma vaccines
is that it is not always feasible to use the autologous tumour to
prepare the vaccine: the tumour specimens may be small, contain-
ing only a small number of intact tumour cells. In an attempt to
solve this problem, we cultured cells from the original tumours.
Using these cell cultures allowed us to enlarge the number of cells
available for vaccination. Moreover, by using cultured cells we
could minimise or even avoid using tissue degrading enzymes,
which might lead to changes in cell surface molecules. By passaging
the cultured cells two to ﬁve times we assured that the vaccine
would include only viable melanoma cells, and that any remaining
undesirable enzymes from the dissociation procedure would be
diluted and removed. Furthermore, culturing the tumour cells
resulted in the preferred reproduction of melanoma cells, thus
assuring that necrotic cells and associated non-tumour cells would
be excluded from the vaccine.
Though our study did not include a control group, the results
disclose a signiﬁcant and relevant correlation between the develop-
ment of a DTH response to unmodiﬁed, autologous melanoma
cells and disease free survival (DFS). A median DFS of 17 months
for patients with a strong positive DTH reaction is signiﬁcantly
better than the median DFS of 9 months for the non-reactive
patients (Table 3). In stage III patients, the respective mean OS
was 19 vs 38 months and the mean DFS – 9.6 vs 20 months. These
differencies were found to be statistically signiﬁcant.
Though we did not originally design our study to discern survival
beneﬁt for patients, over a median follow up period of 34 months
we attained an overall cancer-related survival ratio of 76% (33/43,
with two cancer-unrelated deaths), considerably higher than
reported. It is important to note that patients eligible for adjuvant
treatment with an autologous vaccine are in an unfavourable sub-
group for their stage of disease. For a surgeon to recommend such
treatment, stage III patients must have a macroscopic disease (Nb).
The correlation between DTH and survival has been observed by
the research groups of Berd et al (1986, 1991, 1993) and Baars et al
(2000) using autologous melanoma vaccines, and by the groups of
Morton (1992) using allogeneic melanoma vaccines and of Bystryn
(1992), using shed material melanoma vaccines. DTH is considered
to be a classical CD4+ T cell response, but both CD4+ and CD8+
T cell subsets with anti melanoma reactivity were isolated from skin
biopsies of DTH sites (Waanders et al, 1997). Conversion from a
non-reactive status to a reactive one is associated with the emergence
of MAA-reactive CTLs. We do not consider the DTH to be a mere
representation of an intact cell mediated immunity of the individual,
because before being vaccinated each one of our patients was tested
with four common antigens and demonstrated at least one 5 mm
wide reaction. Injections of autologous lymphocytes cryopreserved
with 10% foetal calf serum caused no skin reaction in any of our
patients, suggesting that their reactions were melanoma speciﬁc.
The BCG that was given as an immunoadjuvant, has probably no
independent signiﬁcant therapeutic effect (Tan et al, 1993).
In conclusion, we found that the adjuvant administration of
autologous melanoma vaccine was associated with the improved
disease-free and overall survival of selected patients that success-
fully attained anti-melanoma reactivity as detected by positive
DTH reactions to injected unmodiﬁed melanoma cells. Melanoma
cell cultures permit this method to be used for patients with small
tumour specimens and yield a puriﬁed tumour cell population.
Obviously, our present study was carried out without any control
groups. With this compromise, the study still supports the idea
that an adjuvant vaccination strategy holds promise for the treat-
ment of high risk melanoma patients.
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